Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
11 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 39(1); March 2007
Prev issue Next issue
Original Articles
Induction Chemotherapy of Docetaxel and Cisplatin for the Elderly Patients with Squamous Cell Carcinoma of the Head and Neck
Young-Jin Choi, Jooseop Chung, Ho-Jin Shin, Goon-Jae Cho, Soo-Geun Wang, Byung-Joo Lee, Byung-Mann Cho, Dong-Won Kim, Hak-Jin Kim, Won Sik Lee, Young-Don Joo, Chang-Hak Sohn
Cancer Res Treat. 2007;39(1):1-5.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.1
AbstractAbstract PDFPubReaderePub
Purpose

Although concurrent chemoradiotherapy (CCRT) has been considered as a standard treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN), this treament is associated with increased toxicities such as mucositis and dermatitis. As a result, the dose intensity can be reduced and interruptions of radiotherapy are more common for CCRT than for sequential treatment, especially for the elderly patients. This prospective study was performed to assess the efficacy and safety profiles of the induction chemotherapy of docetaxel and cisplatin for elderly patients with locally advanced SCCHN.

Materials and Methods

Patients over 65 years of age with locally advanced SCCHN were treated with docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every 21 days. The chemotherapy consisted of two cycles with a third cycle that was administered to the responding patients. Patients who did not respond to initial chemotherapy underwent radiotherapy as a definitive local treatment.

Results

Fifty patients were enrolled in this study and 44 patients were assessable for response and toxicity. The overall response rate was 88%, 16 patients (36%) achieved a complete response and 23 patients (52%) achieved a partial response. After a median follow-up of 24 months (range: 9~38 months) the median disease free period and overall survival period had not yet been reached. The one year and two year survival rates were 89% and 70%, respectively. The most common grade 3/4 adverse event was neutropenia, which occurred in 33 patients (75%) and 4 patients had febrile neutropenia.

Conclusion

Combination chemotherapy of docetaxel and cisplatin is an effective regimen with an acceptable safety profile as the induction treatment for elderly patients suffering with SCCHN.

Citations

Citations to this article as recorded by  
  • Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
    Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Nandini Menon, Atanu Bhattacharjee, Ajay Singh, Zoya Peelay, Shatabdi Chakraborty, Monica Jadhav, Mitali Alone, Priyanka Bhagyavant, Manali Kolkur, Sujay Srinivas, Sudeep Das, Somnat
    European Journal of Cancer.2024; : 113560.     CrossRef
  • Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
    Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Jung Hye Kwon, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun
    BMC Cancer.2020;[Epub]     CrossRef
  • Treatment of inoperable elderly head and neck cancer patients
    Joël Guigay, Hervé Le Caer, Cécile Ortholan, Anne Aupérin, Cécile Michel, Cécile Mertens
    Current Opinion in Oncology.2019; 31(3): 152.     CrossRef
  • Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma
    Francesca De Felice, Luigia Vetrone, Nadia Bulzonetti, Rossella Caiazzo, Francesco Marampon, Daniela Musio, Vincenzo Tombolini
    Medical Oncology.2019;[Epub]     CrossRef
  • Radiotherapy in late elderly (aged 75 or older) patients with paranasal sinus carcinoma: a single institution experience
    Hiroshi Doi, Kazuhiro Kitajima, Masao Tanooka, Tomonori Terada, Kazuma Noguchi, Yasuhiro Takada, Masayuki Fujiwara, Reiichi Ishikura, Norihiko Kamikonya, Shozo Hirota
    European Archives of Oto-Rhino-Laryngology.2016; 273(12): 4485.     CrossRef
  • Treatment of head and neck cancer in the elderly
    Stefan Hartmann, Jennifer R. Grandis
    Expert Opinion on Pharmacotherapy.2016; 17(14): 1903.     CrossRef
  • Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines
    SINDHU VALIYAVEEDAN GOVINDAN, SAFEENA KULSUM, RAMANAN SOMASUNDARA PANDIAN, DEBASHISH DAS, MUKUND SESHADRI, WESLEY HICKS, MONI ABRAHAM KURIAKOSE, AMRITHA SURESH
    Molecular Medicine Reports.2015; 12(2): 3025.     CrossRef
  • The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer
    Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim, Joon-Kyoo Lee, Deok-Hwan Yang, Yeo-Kyeoung Kim, Je-Jung Lee, Sang-Chul Lim, Hyeoung-Joon Kim, Woong-Ki Chung, Ik-Joo Chung
    Cancer Research and Treatment.2007; 39(3): 93.     CrossRef
  • 9,394 View
  • 69 Download
  • 8 Crossref
Close layer
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Res Treat. 2007;39(1):6-9.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.6
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.

Materials and Methods

Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.

Results

37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).

Conclusion

The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
    Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
    Cancer Management and Research.2022; Volume 14: 2825.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • 9,077 View
  • 45 Download
  • 2 Crossref
Close layer
Laparoscopic Assisted Distal Rectal Cancer Resection with Preoperative Concurrent Chemoradiotherapy
Bong Hwa Lee, Mi Young Chang, Sung Kook Park, Taeik Eum, Hyun Joo Shin, Nam Kyu Ro, Chang Nam An, Hae Wan Lee, Lee Su Kim, Hyoung-Chul Park, Hoon Sik Bae, Dae Young Zang, Richard L Whelan
Cancer Res Treat. 2007;39(1):10-15.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.10
AbstractAbstract PDFPubReaderePub
Purpose

Anatomy of deep pelvis, narrow distal margin and tumor invasion into neighbor organ are obstacles for curative radical resection for advanced cancer of distal rectum. Technically, laparoscopic application after downstaging the tumor with preoperative concurrent chemotherapy (CCRT) may give a solution to overcome the anatomical difficulties. We compared the results of laparoscopic surgery in the patients who received CCRT with those of patients who had conventional surgery.

Materials and Methods

A continuous infusion of 5FU plus leucovorin and radiotherapy (50.4 Gy) in 28 fractions was given each patient as CCRT. They underwent D2 radical resection with TME and ANP for the rectal cancer in 4 weeks.

Results

Thirty three patients had laparoscopic resection such as LAR, colo-anal anastomosis and APR. The results were compared with 12 cases of the conventional resections. As a result of preoperative CCRT, the cancer was down-staged in 71%. Two year disease free survival was 75% and 74% in the group of conventional and laparoscopic resection, respectively (p=0.427). Ileus, voiding difficulty and leakage after surgery were not different between two groups. Weakness of ejaculation was noted in 9~11% of both groups. The DFS of the preoperative CCRT followed by radical resection in the groups with a response was more favorable than that in the group with progressive or stable disease.

Conclusion

Radical resection of advanced distal rectal cancer could be done with performing a laparoscopic assisted operation after CCRT induced down-staging. We may suggest that laparoscopic assisted resection is a good treatment option as it doesn't increase the complications and it has a compatible survival rate to conventional surgery.

Citations

Citations to this article as recorded by  
  • DPYD,TYMS,TYMP,TK1, andTK2Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
    Ming-Yii Huang, Chan-Han Wu, Chun-Ming Huang, Fu-Yen Chung, Ching-Wen Huang, Hsiang-Lin Tsai, Chin-Fan Chen, Shiu-Ru Lin, Jaw-Yuan Wang
    BioMed Research International.2013; 2013: 1.     CrossRef
  • 9,466 View
  • 48 Download
  • 1 Crossref
Close layer
Radiation-induced Necrosis Deteriorating Neurological Symptoms and Mimicking Progression of Brain Metastasis after Stereotactic-guided Radiotherapy
Young Zoon Kim, Dae Yong Kim, Heon Yoo, Hee Seok Yang, Sang Hoon Shin, Eun Kyung Hong, Kwan Ho Cho, Seung Hoon Lee
Cancer Res Treat. 2007;39(1):16-21.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.16
AbstractAbstract PDFPubReaderePub
Purpose

Although radiation-induced necrosis (RIN) is not a tumor in itself, the lesion progressively enlarges with mass effects and diffuse peritumoral edema in a way that resembles neoplasm. To identify the RIN that mimics progression of brain metastasis, we performed surgical resections of symptomatic RIN lesions.

Meterials and Methods

From June 2003 to December 2005, 7 patients received stereotactic-guided radiotherapy (SRT) for metastatic brain tumor, and they later underwent craniotomy and tumor resection due to the progressive mass effects and the peritumoral edema that caused focal neurological deficit. On MR imaging, a ring-like enhanced single lesion with massive peritumoral edema could not be distinguished from progression of brain metastasis.

Results

Four patients had non-small cell lung cancer, 2 patients had colorectal cancer and 1 patient had renal cell carcinoma. The mean tumor volume was 8.7 ml (range: 3.0~20.7 ml). The prescribed dose of SRT was 30 Gy with 4 fractions for one patient, 18 Gy for two patients and 20 Gy for the other four patients. The four patients who received SRT with a dose of 20 Gy had RIN with or without microscopic residual tumor cells.

Conclusions

Early detection of recurrent disease after radiotherapy and identifying radiation-induced tissue damage are important for delivering adequate treatment. Therefore, specific diagnostic tools that can distinguish RIN from progression of metastatic brain tumor need to be developed.

Citations

Citations to this article as recorded by  
  • Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis
    Ashish H Shah, Anil K Mahavadi, Alexis Morell, Daniel G Eichberg, Evan Luther, Christopher A Sarkiss, Alexa Semonche, Michael E Ivan, Ricardo J Komotar
    Neuro-Oncology Practice.2020; 7(1): 94.     CrossRef
  • OAR sparing 3D radiotherapy planning supported by fMRI brain mapping investigations
    Gábor Opposits, Csaba Aranyi, Csaba Glavák, Zsolt Cselik, Lajos Trón, Dávid Sipos, Janaki Hadjiev, Ervin Berényi, Imre Repa, Miklós Emri, Árpád Kovács
    Medical Dosimetry.2020; 45(4): e1.     CrossRef
  • The Role of Navigated Transcranial Magnetic Stimulation Motor Mapping in Adjuvant Radiotherapy Planning in Patients With Supratentorial Brain Metastases
    Maximilian J. Schwendner, Nico Sollmann, Christian D. Diehl, Markus Oechsner, Bernhard Meyer, Sandro M. Krieg, Stephanie E. Combs
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases
    Alireza M. Mohammadi, Jason L. Schroeder, Lilyana Angelov, Samuel T. Chao, Erin S. Murphy, Jennifer S. Yu, Gennady Neyman, Xuefei Jia, John H. Suh, Gene H. Barnett, Michael A. Vogelbaum
    Journal of Neurosurgery.2017; 126(3): 735.     CrossRef
  • Nonthermal ablation in the rat brain using focused ultrasound and an ultrasound contrast agent: long-term effects
    Nathan McDannold, Yongzhi Zhang, Natalia Vykhodtseva
    Journal of Neurosurgery.2016; 125(6): 1539.     CrossRef
  • Analysis of risk and predictors of brain radiation necrosis after radiosurgery
    Hongqing Zhuang, Yi Zheng, Junjie Wang, Joe Y. Chang, Xiaoguang Wang, Zhiyong Yuan, Ping Wang
    Oncotarget.2016; 7(7): 7773.     CrossRef
  • Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?
    Ashish H. Shah, Brian Snelling, Amade Bregy, Payal R. Patel, Danoushka Tememe, Rita Bhatia, Evelyn Sklar, Ricardo J. Komotar
    Journal of Neuro-Oncology.2013; 112(2): 141.     CrossRef
  • Comparison of Swallowing Functions Between Brain Tumor and Stroke Patients
    Dae Hwan Park, Min Ho Chun, Sook Joung Lee, Yoon Bum Song
    Annals of Rehabilitation Medicine.2013; 37(5): 633.     CrossRef
  • 10,304 View
  • 60 Download
  • 8 Crossref
Close layer
Enhancement of Plasmacytoma Cell Growth by Ascorbic Acid is Mediated Via Glucose 6-phosphate Dehydrogenase
Woo Suk Koh, Woo Hyuck Choi, Sook Ja Lee, Chaehwa Park, Chan H Park
Cancer Res Treat. 2007;39(1):22-29.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.22
AbstractAbstract PDFPubReaderePub
Purpose

We investigated the mechanism by which some types of cancer cells grow faster in the presence of ascorbic acid supplementation.

Materials and Methods

Adj.PC-5, a mouse plasmacytoma cell, is known to show ascorbic acid-dependent growth and was chosen as a test system. The growth of cancer cells was measured by the colony number on soft agar or the cellular proliferation in suspension culture. The ascorbate level was measured by a high performance liquid chromatography system with an electrochemical detector. Glucose 6-phosphate dehydrogenase was analyzed both on the specific enzyme activity level and on the transcription level by performing Northern blot analysis.

Results

Ascorbyl 2-phosphate among the ascorbate derivatives was the most efficient in stimulating cell growth. The intracellular and extracellular ascorbate concentrations following treatment with either ascorbate or ascorbyl 2-phosphate suggest that the superiority of ascorbyl 2-phosphate for stimulating cell growth may be due to its slow conversion to ascorbate in the culture medium. The steady transformation to ascorbate ensures sustained levels of ascorbate in the culture medium and thereby maximizes the growth stimulatory effect of ascorbate. Ascorbyl 2-phosphate markedly enhanced, in a concentration-and time-dependent manner, mRNA synthesis as well as the enzymatic activity of glucose 6-phosphate dehydrogenase, which is known to be a rate-limiting enzyme in cell growth. On the other hand, simultaneous addition of dehydroisoandrosterone, a well- known inhibitor of glucose 6-phosphate dehydrogenase, to the culture medium abrogated the growth stimulation by ascorbyl 2-phosphate, and it also reduced the glucose 6-phosphate dehydrogenase activity proportionately.

Conclusions

The results from this study suggest that enhanced glucose 6-phosphate dehydrogenase activity may at least in part explain the stimulation of cell growth by ascorbate or ascorbyl 2-phosphate.

Citations

Citations to this article as recorded by  
  • Glucose-6-phosphate dehydrogenase – beyond the realm of red cell biology
    H.-Y. Ho, M.-L. Cheng, D. T.-Y. Chiu
    Free Radical Research.2014; 48(9): 1028.     CrossRef
  • Ascorbic acid: Chemistry, biology and the treatment of cancer
    Juan Du, Joseph J. Cullen, Garry R. Buettner
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2012; 1826(2): 443.     CrossRef
  • 7,586 View
  • 49 Download
  • 2 Crossref
Close layer
Analysis of Cellular Changes Resulting from Forced Expression of Dickkopf-1 in Hepatocellular Carcinoma Cells
Mi Hee Kwack, Sun Young Hwang, In Seok Jang, Sang Uk Im, Jin Oh Kim, Moon Kyu Kim, Jung Chul Kim, Young Kwan Sung
Cancer Res Treat. 2007;39(1):30-36.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.30
AbstractAbstract PDFPubReaderePub
Purpose

Recent studies have shown that Dickkopf-1 (DKK-1) is overexpressed in some tumors, including hepatocellular carcinoma. However, the role of increased DKK-1 in these tumors is not known. In this study, the DKK-1 expression in hepatocellular carcinoma (HCC) cell lines was evaluated and the effect of DKK-1 overexpression in HCC cell lines was studied.

Materials and Methods

The expression of DKK-1 in hepatocellular carcinoma cell lines was evaluated by RT-PCR. Stable cell lines that overexpressed DKK-1 were established. Cell growth, adhesion, migration and invasion assays were performed.

Results

RT-PCR analysis showed that 5 out of 8 HCC cell lines expressed DKK-1. The forced expression of DKK-1 suppressed the growth of cells and increased the population of cells in the sub-G1 phase. In addition, DKK-1 reduced the cellular adhesion capacity to collagen type I and fibronectin, and it increased migratory capacity. However, overexpression of DKK-1 did not increase the invasion capacity of the HCC cell line.

Conclusion

Collectively, our data suggest that overexpression of DKK-1 affects the biology of HCC cells.

Citations

Citations to this article as recorded by  
  • Non-invasive biomarkers for the detection of hepatocellular carcinoma
    Daniela Campion, Alessandra Tucci, Paola Ponzo, Gian Paolo Caviglia
    Minerva Biotecnologica.2019;[Epub]     CrossRef
  • DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1
    Maha Fezza, Mayssam Moussa, Rita Aoun, Rita Haber, George Hilal, Masaru Katoh
    PLOS ONE.2019; 14(9): e0223252.     CrossRef
  • MicroRNA-320a downregulation mediates human liver cancer cell proliferation through the Wnt/β-catenin signaling pathway
    Caicheng Lu, Zengwei Liao, Minxian Cai, Guirong Zhang
    Oncology Letters.2017; 13(2): 573.     CrossRef
  • Musashi1 regulates survival of hepatoma cell lines by activation of Wnt signalling pathway
    Kunlun Chen, Qing Gao, Wei Zhang, Zhongwei Liu, Jiangyi Cai, Ying Liu, Jinkai Xu, Jie Li, Yi Yang, Xin Xu
    Liver International.2015; 35(3): 986.     CrossRef
  • Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma
    Seung Up Kim, Jeon Han Park, Hyon-Suk Kim, Jae Myun Lee, Hyun Gyu Lee, Hyemi Kim, Sung Hoon Choi, Shinhwa Baek, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jong Doo Lee, Kwang-Hyub Han
    Yonsei Medical Journal.2015; 56(5): 1296.     CrossRef
  • Serum level of DKK-1 and its prognostic potential in non–small cell lung cancer
    Liang-liang Dong, Lu-yun Qu, Li-yan Chu, Xiao-hui Zhang, Ying-hui Liu
    Diagnostic Pathology.2014;[Epub]     CrossRef
  • 11,074 View
  • 42 Download
  • 6 Crossref
Close layer
Case Reports
Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim
Cancer Res Treat. 2007;39(1):37-39.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.37
AbstractAbstract PDFPubReaderePub

A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.

Citations

Citations to this article as recorded by  
  • Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
    Navneet Singh
    World Journal of Clinical Oncology.2014; 5(5): 858.     CrossRef
  • Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
    Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
    Tuberculosis and Respiratory Diseases.2011; 71(4): 286.     CrossRef
  • 9,757 View
  • 61 Download
  • 2 Crossref
Close layer
Orbital Infiltration as the First Site of Relapse of Primary Testicular T-cell Lymphoma
Hyun Jung Jun, Won Seog Kim, Ji Hyun Yang, Seong Yoon Yi, Young H. Ko, Jeeyun Lee, Chul Won Jung, Se Woong Kang, Keunchil Park
Cancer Res Treat. 2007;39(1):40-43.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.40
AbstractAbstract PDFPubReaderePub

A 43-year-old male presented with a painless left testicular mass. The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u). According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement. After first-line chemotherapy with four courses of the CHOP regimen and this was followed by involved-field radiotherapy, he achieved complete remission. Two months later, disease recurred to the left ciliary body of the left eye without evidence of involvement at other sites. Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding. Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

Citations

Citations to this article as recorded by  
  • Relapse of Ocular Lymphoma following Primary Testicular Diffuse Large B-cell Lymphoma
    Hye Ji Kwon, Joo Yong Lee
    Journal of Retina.2023; 8(1): 58.     CrossRef
  • Chronic lymphocytic leukemia and concurrent seminoma in the same testis
    Kosuke Miyai, Fumihisa Kumazawa, Kimiya Sato, Hitoshi Tsuda
    Journal of Pathology and Translational Medicine.2022; 56(1): 48.     CrossRef
  • Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas
    Natalia Zing, Thais Fischer, Massimo Federico, Carlos Chiattone, Andrés J.M. Ferreri
    Critical Reviews in Oncology/Hematology.2021; 167: 103496.     CrossRef
  • Primary testicular T-lymphoblastic lymphoma in a child
    Yongren Wang, Jian Li, Yongjun Fang
    Medicine.2020; 99(26): e20861.     CrossRef
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified and Concurrent Seminoma in Testis
    Junichi Kitagawa, Naoe Goto, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Takeshi Hara, Katsuyoshi Takata, Yasuharu Sato, Tadashi Yoshino, Hisashi Tsurumi
    Journal of Clinical and Experimental Hematopathology.2015; 55(3): 169.     CrossRef
  • Primary testicular lymphoma
    Chan Y. Cheah, Andrew Wirth, John F. Seymour
    Blood.2014; 123(4): 486.     CrossRef
  • Testicular lymphoma, intraocular (Vitreoretinal) lymphoma, and brain lymphoma: Involvement of three immunoprivileged sites in one patient
    Jacob Pe'er, Jacob M. Rowe, Shahar Frenkel, Eldad J. Dann
    American Journal of Hematology.2010; 85(8): 631.     CrossRef
  • 9,906 View
  • 68 Download
  • 7 Crossref
Close layer
Correction
Correction: Long Term Trends and the Future Gastric Cancer Mortality in Korea: 1983~2013
Yunhee Choi, Jin Gwack, Yeonju Kim, Jisuk Bae, Jae-Kwan Jun, Kwang-Pil Ko, Keun-Young Yoo
Cancer Res Treat. 2007;39(1):44-46.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.44
Corrects: Cancer Res Treat 2006;38(1):7
PDFPubReaderePub
  • 5,710 View
  • 45 Download
Close layer
Retractions
Retraction: Comparison of As2O3 and As4O6 in the Detection of SiHa Cervical Cancer Cell G rowth Inhibition Pathway
Yong Wook Kim, Su Mi Bae, Keun Ho Lee, Joon Mo Lee, Sung Eun Namkoong, Insu P. Lee, Chong Kook Kim, Jeong-Sun Seo, Jeong-Im Sin, Yong-Wan Kim, Woong Shick Ahn
Cancer Res Treat. 2007;39(1):47-47.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.47
Retracts: Cancer Res Treat 2004;36(4):255
PDFPubReaderePub
  • 6,785 View
  • 57 Download
Close layer
Retraction: Tetraarsenic Oxide-mediated Apoptosis in a Cervical Cancer Cell Line, SiHa
Jeong Kim, Su-Mi Bae, Dae-Seog Lim, Sun-Young Kwak, Chang-Ki Lee, Yong-Seok Lee, IL-Ju Bae, Jin-Young Yoo, Young-Joo Lee, Chong-Kook Kim, Woong-Shick Ahn
Cancer Res Treat. 2007;39(1):48-48.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.48
Retracts: Cancer Res Treat 2005;37(5):307
PDFPubReaderePub
  • 7,406 View
  • 53 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP